Bayer CEO Threatens US Glyphosate Halt as Legal Drag Intensifies
05.06.2026 - 22:13:56 | boerse-global.de
The German pharmaceutical and agriculture giant finds itself in a deepening strategic bind. On one side, operating performance is improving; on the other, legal liabilities continue to devour cash and dominate the narrative. Chief Executive Bill Anderson has now escalated the conflict by warning of a complete halt to glyphosate production in the United States unless a durable legal solution is reached. With over 100,000 Roundup lawsuits still pending, the threat is not empty — a production stop would hit American farming hard and underscore how legacy litigation is bleeding into core operations.
The stock itself is treading water at a critical technical juncture. In Frankfurt trading, shares edged up 1.36 percent to €35.82, hovering practically on the 200-day moving average of €35.80. On a monthly view, the stock is still down 7.01 percent, while year-to-date losses stand at roughly 5.80 percent. The secondary article reported a slightly higher level of €36.12 with a 2 percent daily gain, reflecting intraday volatility. Market capitalisation sits at about €33.5 billion.
Operationally, the first quarter of 2026 offered real encouragement. Net profit rose to €2.76 billion, and the Crop Science division posted currency-adjusted sales growth of 6.8 percent, supported by lucrative licensing deals and a robust performance in Consumer Health. Earnings per share comfortably beat expectations. Yet the cash flow statement tells a more troubling story: free cash flow came in at minus €2.32 billion, largely due to roughly €2 billion in settlement payments linked to PCB and glyphosate claims. Analysts see potential for EBITDA to surpass €10 billion by 2028, but that scenario depends on a credible easing of legal costs — something that remains elusive.
Should investors sell immediately? Or is it worth buying Bayer?
The legal calendar is dense and fraught with risk. By end of June, a landmark decision from the US Supreme Court on glyphosate pre-emption is expected. Should Bayer prevail, it could pave the way for a comprehensive resolution. Then, in July, a fairness hearing for the $7.25 billion Roundup class-action settlement is scheduled. In parallel, plaintiff lawyers are trying to move cases from Missouri to a federal court in California known for being hostile to Bayer. Management is fighting that move in court while Anderson pressures Washington.
A new front has also opened in the agricultural business. Reports emerged of fresh lawsuits linked to genetically modified corn seed, adding another layer of legal exposure at a time when the company is trying to shift investor focus away from litigation and toward operational strength. mwb research maintains a price target of €52.00, arguing that recent legal headlines are sentiment-driven and the current share price already embeds a high risk discount.
Major shareholders are running out of patience. Union Investment has voiced sharp frustration, demanding margins rather than visions. The call for returns over rhetoric reflects a growing unease across the shareholder base. Yet Bayer’s management continues to rule out a spin-off of the Monsanto agriculture unit, insisting it will resolve the legal knots within the current structure — even as it says it is keeping all options open.
The conflict between improved fundamentals and unrelenting legal overhang keeps the stock pinned near its long-term moving average. A clean break above €35.80 would brighten the chart, while a failure risks confirming the recent rally as a mere bear-market bounce. Until the Supreme Court rules or the July settlement hearing clarifies the path, Bayer remains caught between a robust operational engine and a legal drag that shows no sign of letting up.
Ad
Bayer Stock: New Analysis - 5 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
